Management of Peyronie's Disease after Collagenase (Xiaflex:®)

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|16|5|484-494

ISSN： 1389-4501

Source： Current Drug Targets, Vol.16, Iss.5, 2015-01, pp. : 484-494

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacological Management of Peyronie's Disease

By Trost Landon W.   Gur Serap   Hellstrom Wayne J.G  

Drugs, Vol. 67, Iss. 4, 2007-01 ,pp. : 527-545

Adis International

Access to resources Recommend Favorite

Peyronie’s disease: an update of the medical management

By Maan Zafar   Arya Manit   Shergill Iqbal   Joseph Jean V   Patel Hitendra RH  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 4, 2004-04 ,pp. : 799-805

Informa Healthcare

Access to resources Recommend Favorite

Peyronie's disease: perspectives on therapeutic targets

By Abdel-Hamid Ibrahim A   Anis Tarek  

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 8, 2011-08 ,pp. : 913-929

Informa Healthcare

Access to resources Recommend Favorite

Carvedilol: First report of Peyronie's disease: case report

By  

Reactions Weekly, Vol. 1, Iss. 1229, 2008-01 ,pp. : 8-9

Adis International

Access to resources Recommend Favorite

Current status and new developments in Peyronie's disease: medical, minimally invasive and surgical treatment options

By Gur Serap   Limin Ma   Hellstrom Wayne JG  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 6, 2011-04 ,pp. : 931-944

Informa Healthcare

Access to resources Recommend Favorite